AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01625715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
Study NCT03057730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
Study NCT02615249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Metal Allergen Epicutaneous Patch
Description: 48 hour application of metal allergen patch to diagnose contact dermatitis
Study NCT01258439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir plus truvada
Description: raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
Study NCT01258439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
Description: Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
Study NCT00780039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study NCT02961725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC
Description: UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
Study NCT03294304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
Study NCT03294304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
Study NCT03294304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
Study NCT02196103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double balloon cervical catheter
Study NCT04257617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1201
Description: Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
Study NCT01258855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT01576471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Description: TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
Study NCT01258855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01576471 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
Study NCT04614792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Non-invasive brain stimulation or neuromodulation.
Study NCT01258855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study NCT00382070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg taken orally once daily for 5 years
Study NCT00382070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once daily for 5 years
Study NCT01552889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
Study NCT01333189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-bearing biofeedback exercise
Description: Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games.
Study NCT01333189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care exercise
Description: Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
Study NCT00488527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
Study NCT01765621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DDI+ System and Pharmacogenetic Data
Study NCT02360501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/㎡,d1
Study NCT02360501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/㎡,d1-3
Study NCT02360501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000mg/㎡,d1-14
Study NCT00879359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, paclitaxel, and bevacizumab
Description: All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
Study NCT02729961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT02729961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO
Study NCT02729961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01309880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lens
Description: Investigational silicone hydrogel contact lens worn on a daily wear basis
Study NCT01309880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Air Optix Aqua contact lens worn on a daily wear basis
Study NCT03149419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Study NCT03149419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study NCT03763383 — intervention group
Intervention type: PROCEDURE
Intervention: Lateral Arm Flap
Description: Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
Study NCT00855582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: tablet once daily by mouth for 12 weeks.
Study NCT00855582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
Study NCT03083379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric Incentive Spirometry
Description: A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~* Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~* Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~* Incentive Spirometry therapy and monitoring session will last about 15 minutes
Study NCT03083379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EzPAP® POSITIVE AIRWAY PRESSURE
Description: * A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~* Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~* EzPAP® therapy and monitoring sessions will last about 15 minutes
Study NCT01850940 — intervention group
Intervention type: DRUG
Intervention: Tolvaptan
Description: Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
Study NCT02729961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04970680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glossopharyngeal nerve block
Description: glossopharyngeal nerve block either blindly or using the ultrasonic technique
Study NCT00327444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
Study NCT01850940 — intervention group
Intervention type: OTHER
Intervention: conventional thearpy
Description: conventional therapy with salt limitation ,et al
Study NCT00327444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
Study NCT00327444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
Study NCT00327444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
Study NCT03490786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT-001
Description: PK, PD Study to Determine Safety of Escalating Doses of GT-001
Study NCT00066781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00066781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01191996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MIS416
Description: MIS416 intravenously every week
Study NCT03140631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine Sulfate
Description: Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
Study NCT00959153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LithoSpace Extracorporeal Shockwave Lithotripter
Description: Shockwave therapy to break up kidney stones
Study NCT02906540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpubic symphysis reset therapy group
Description: The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
Study NCT02906540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy group
Description: The patients in the control group will undergo physiotherapy and a sham treatment.
Study NCT03315247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based CBT
Description: The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
Study NCT00834964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting
Study NCT00834964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting
Study NCT03807037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienols
Description: Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
Study NCT03807037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo to be administered orally at 1 capsule, twice daily
Study NCT02561611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
Study NCT02091713 — intervention group
Intervention type: OTHER
Intervention: Functional movement screen
Description: The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
Study NCT02175095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
Study NCT02175095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FLT-PET
Description: \[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.
Study NCT02175095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET
Description: \[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.
Study NCT03040362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-lasmiditan
Description: \[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
Study NCT04567836 — intervention group
Intervention type: OTHER
Intervention: Investigation of the prevalence of test positivity
Description: The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses .
Study NCT03692273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Luminis ultrapulse fractional ablative carbon dioxide laser
Description: This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
Study NCT03692273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.5mm punch biopsy
Description: punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
Study NCT00659438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib)
Description: 300mg orally, once daily
Study NCT00659438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg orally, once daily
Study NCT00659438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bicalutamide
Description: 150mg orally, once daily
Study NCT00659438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, once daily
Study NCT03560895 — intervention group
Intervention type: DEVICE
Intervention: cuffed endotracheal tube
Description: Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
Study NCT03560895 — intervention group
Intervention type: DEVICE
Intervention: Uncuffed endotracheal tube
Description: Patients will be anesthetized using uncuffed endotracheal tube
Study NCT05109390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study NCT05109390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral capsule.
Study NCT05109390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral capsule.
Study NCT05109390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Chewable tablet.
Study NCT05109390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum/Magnesium Hydroxide/Simethicone
Description: Chewable tablet.
Study NCT05109390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral, delayed-release capsule.
Study NCT05955742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: The operator prepared the glide path using a #15K-type stainless-steel hand file.
Study NCT05955742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProGlider
Description: The operator prepared the glide path using the ProGlider file.
Study NCT05955742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveOne Gold Glider
Description: The operator prepared the glide path using the WaveOne Gold Glider file.
Study NCT01432639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation program
Description: The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
Study NCT03501212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Anesthetic
Description: EMLA Cream 2.5 gr applied to both wrists
Study NCT03501212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Cream 2.5gr applied to both wrist
Study NCT00834119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
Study NCT00834119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
Study NCT02119208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity and timing of exercise
Study NCT02164565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) treatment
Description: Tranexamic Acid (TXA) treatment